nach oben

Erschienen in:

01.06.2012

Differential Role of Estrogen Receptor Beta in Early Versus Metastatic Non-small Cell Lung Cancer

verfasst von: Sri Navaratnam, Georgios Skliris, Gefei Qing, Shantanu Banerji, Ketan Badiani, Dongsheng Tu, Penelope A. Bradbury, Natasha B. Leighl, Frances A. Shepherd, Janet Nowatzki, Alain Demers, Leigh Murphy

Erschienen in: Discover Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Although women have an increased susceptibility to lung cancer, they also have a favorable clinical outcome. This may in part be due to female specific genetic and hormonal factors. In the present study, expression of ER-beta was investigated by immunohistochemistry using tissue samples from two cohorts: non-small cell lung cancer (NSCLC) diagnosed in 1999 in Manitoba and advanced NSCLC patients from the NCIC-CTG BR.18 trial. In the Manitoba cohort assessable tissue samples available in 79 patients (32 females and 47 males) and the majority (75%) had early stage disease. Fifty-one percent of patients expressed high levels of ER-beta (defined by ≥60, the median immunohistochemistry score) and its expression was comparable in males and females. The 3-year overall survival of the group was 53% and males had significantly worse survival compared to females (HR = 2.37, 95%CI 1.15–4.91, P = 0.02). Higher ER-beta 1 expression was associated with better survival in both univariate (HR = 0.41, 95%CI 0.21–0.80, P = 0.009) and in multivariate (HR = 0.37, 95%CI 0.18–0.77, P = 0.008) analysis. In the NCIC-CTG cohort that were more often later stage, assessable tissue samples from 48 cases were available however higher ER-beta 1 expression correlated with poorer survival (HR = 1.94, 95%CI 1.01–3.75 P = 0.047). These results suggest a differential impact of ER-beta 1 expression on clinical outcome by disease stage, that needs to be explored further and may explain contradictory observations reported in the literature.

Thomas L, Doyle L, Edelman M (2005) Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest 128:370–381PubMedCrossRef

Gasperino J, Rom W (2004) Gender and lung cancer. Clin Lung Cancer 5:353–359PubMedCrossRef

Patel J (2005) Lung cancer in women. J Clin Oncol 23:3212–3218PubMedCrossRef

Wheatley-Price P, Blackhall F, Lee SM, Ma C, Ashcroft L, Jitlal M, Qian W, Hackshaw A, Rudd R, Booton R et al (2010) The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol 21:847–852

Wheatley-Price P, Le Maitre A, Ding K, Leighl N, Hirsh V, Seymour L, Bezjak A, Shepherd FA (2010) The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials. J Thorac Oncol 5(5):640–648PubMed

Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, Kim HJ, Yoon H, Lee CT, Jheon S et al. (2011) Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer. A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer. doi:10.1016/j.lungcan.2011.11.008

Patrone C, Cassel T, Pettersson K, Piao Y, Cheng G, Ciana P, Maggi A, Warner M, Gustafsson J, Nord M (2003) Regulation of postnatal lung development and homeostasis by estrogen receptor beta. Mol Cell Biol 23:8542–8552PubMedCrossRef

Dougherty S, Mazhawidza W, Bohn A, Robinson K, Mattingly K, Blankenship K, Huff M, McGregor W, Klinge C (2006) Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocr Relat Cancer 13:113–134PubMedCrossRef

Ishibashi H, Suzuki T, Suzuki S, Niikawa H, Lu L, Miki Y, Moriya T, Hayashi S, Handa M, Kondo T et al (2005) Progesterone receptor in non-small cell lung cancer—a potent prognostic factor and possible target for endocrine therapy. Cancer Res 65:6450–6458PubMedCrossRef

10.

Wu C, Chang Y, Shih J, Lee Y (2005) The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 130:979–986PubMedCrossRef

11.

Stabile L, Davis A, Gubish C, Hopkins T, Luketich J, Christie N, Finkelstein S, Siegfried J (2002) Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62:2141–2150PubMed

12.

Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, Ishikawa Y, Yamori T, Iwase H, Fujii Y et al (2001) Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 285:340–347PubMedCrossRef

13.

Pietras R, Marquez D, Chen H, Tsai E, Weinberg O, Fishbein M (2005) Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70:372–381PubMedCrossRef

14.

Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, Ono I, Minamiya Y, Ogawa J (2005) Estrogen receptor A and B are prognostic factors in non small cell lung cancer. Clin Cancer Res 11:5084–5089PubMedCrossRef

15.

Murphy L, Watson P (2006) Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer 13:327–334PubMedCrossRef

16.

Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson J (2002) Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 62(17):4849–4853PubMed

17.

Fuqua S, Schiff R, Parra I, Friedrichs W, Su J, McKee D, Slentz-Kesler K, Moore L, Willson T, Moore J (1999) Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 59:5425–5428PubMed

18.

Peng B, Lu B, Leygue E, Murphy L (2003) Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol 30:13–29PubMedCrossRef

19.

Saji S, Omoto Y, Shimizu C, Horiguchi S, Watanabe T, Funata N, Hayash S, Gustafsson J, Toi M (2002) Clinical impact of assay of estrogen receptor beta cx in breast cancer. Breast Cancer Res Treat 9:303–307

20.

Abe K, Miki Y, Ono K, Mori M, Kakinuma H, Kou Y, Kudo N, Koguchi M, Niikawa H, Suzuki S et al (2010) Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum Pathol 41(2):190–198PubMedCrossRef

21.

Weinberg O, Marquez-Garban D, Fishbein M, Goodglick L, Garban H, Dubinett S, Pietras R (2005) Aromatase inhibitors in human lung cancer therapy. Cancer Res 65:11287–11291PubMedCrossRef

22.

Mauri D, Pavlidis N, Polyzos N, Ioannidis J (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98:1285–1291PubMedCrossRef

23.

Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S, Hoang T, Dubey S, Marcotte SM, Siegfried JM (2009) Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 64(1):51–59PubMedCrossRef

24.

Stabile L, Lyker J, Gubish C, Zhang W, Grandis J, Siegfried J (2005) Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65:1459–1470PubMedCrossRef

25.

Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J et al (2005) Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 23(12):2831–2839PubMedCrossRef

26.

Skliris G, Leygue E, Curtis-Snell L, Watson P, Murphy L (2006) Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 95:616–626PubMedCrossRef

27.

Murphy LC, Cherlet T, Adeyinka A, Niu Y, Snell L, Watson P (2004) Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo. Clin Cancer Res 10:1354–1359PubMedCrossRef

28.

Weitsman G, Skliris G, Ung K, Peng B, Younes M, Watson P, Murphy L (2006) Assessment of multiple different oestrogen receptor b antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res Treat 100:23–31PubMedCrossRef

29.

Skliris G, Parkes A, Limer J, Burdall S, Carder P, Speirs V (2002) Evaluation of seven oestrogen receptor b antibodies for immunohistochemistry, western blotting and flow cytometry in human breast tissue. J Pathol 197:155–162PubMedCrossRef

30.

Leav I, Lau K-M, Adams J, McNeal J, Taplin M-E, Wang J, Singh H, Ho S-M (2001) Comparative studies of the estrogen receptor b and a and the androgen receptor in normal human prostate glands, dysplasia and in primary and metastatic carcinoma. Am J Pathol 159(1):79–92PubMedCrossRef

31.

Siegfried JM, Hershberger PA, Stabile LP (2009) Estrogen receptor signaling in lung cancer. Semin Oncol 36(6):524–531PubMedCrossRef

32.

Schwartz AG, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J, Brooks S (2005) Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 11(20):7280–7287PubMedCrossRef

33.

Skov BG, Fischer BM, Pappot H (2008) Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 59(1):88–94PubMedCrossRef

34.

Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C et al (2009) Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 15(17):5359–5368PubMedCrossRef

35.

Omoto Y, Kobayashi S, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Gustafsson J, Iwase H (2002) Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 38(3):380–386PubMedCrossRef

36.

Palmieri C, Lam E, Mansi J, MacDonald C, Shousha S, Madden P, Omoto Y, Sunters A, Warner M, Gustafsson J et al (2004) The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 10(7):2421–2428PubMedCrossRef

37.

Leung Y, Mak P, Hassan S, Ho S (2006) Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci U S A 103:13162–13167PubMedCrossRef

38.

Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT et al (2008) Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14(16):5228–5235PubMedCrossRef

39.

Moore J, McKee D, Slentz-Kesler K, Moore L, Jones S, Horne E, Su J-L, Kliewer S, Lehmann’ J, Willson T (1998) Cloning and characterization of human estrogen receptor b isoforms. Biochem Biophys Res Commun 247:75–78PubMedCrossRef

40.

Ali G, Donati V, Loggini B, Servadio A, Dell’Omodarme M, Prati MC, Camacci T, Lucchi M, Melfi F, Mussi A et al (2008) Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. Hum Pathol 39(10):1465–1473PubMedCrossRef

41.

Kelly RJ, Morris JC (2010) Transforming growth factor-beta: a target for cancer therapy. J Immunotoxicol 7:15–26PubMedCrossRef

42.

Chang EC, Frasor J, Komm B, Katzenellenbogen BS (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147(10):4831–4842PubMedCrossRef

43.

Skliris G, leygue E, Watson P, Murphy L (2008) Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol 109:1–10PubMedCrossRef

44.

Savinov A, Remacle A, Golubkov V, Krajewska M, Kennedy S, Duffy M, Rozanov D, Krajewski S, Strongin A (2006) Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res 66:2716–2724PubMedCrossRef

45.

Tateishi Y, Sonoo R, Sekiya Y, Sunahara N, Kawano M, Wayama M, Hirota R, Kawabe Y, Murayama A, Kato S et al (2006) Turning off estrogen receptor beta-mediated transcription requires estrogen-dependent receptor proteolysis. Mol Cell Biol 26:7966–7976PubMedCrossRef

Titel: Differential Role of Estrogen Receptor Beta in Early Versus Metastatic Non-small Cell Lung Cancer
verfasst von: Sri Navaratnam
Georgios Skliris
Gefei Qing
Shantanu Banerji
Ketan Badiani
Dongsheng Tu
Penelope A. Bradbury
Natasha B. Leighl
Frances A. Shepherd
Janet Nowatzki
Alain Demers
Leigh Murphy
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: Discover Oncology / Ausgabe 3/2012
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-012-0105-y

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Differential Role of Estrogen Receptor Beta in Early Versus Metastatic Non-small Cell Lung Cancer

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Androgen Resistance in Female Mice Increases Susceptibility to DMBA-Induced Mammary Tumors

Glucocorticoids Regulate Gene Expression and Repress Cellular Proliferation in Human Uterine Leiomyoma Cells

Effects of Oestrogen on MicroRNA Expression in Hormone-Responsive Breast Cancer Cells

Translational Highlights

Membrane Progesterone Receptors (mPRs) Mediate Progestin Induced Antimorbidity in Breast Cancer Cells and Are Expressed in Human Breast Tumors

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie